AstraZeneca Shakeup Of China Business Unit Steers Focus Away From Generics To Innovative Drugs
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca will dissolve its Broad Market business unit in China by merging it with primary care and move away from attracting business for branded generics in tier-3 rural markets, putting flesh on new CEO Pascal Soriot’s plan to focus on innovation.